SCHEMBL20837293

SCHEMBL20837293

Nc1ccccc1NCC1CCCC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.53
KDM4E B2RXH2 3/20 0.53
GAA P10253 3/20 0.53
APP P05067 2/20 0.47
HDAC3 O15379 1/20 0.46
HDAC1 Q13547 1/20 0.46
HDAC2 Q92769 1/20 0.46
UTS2R Q9UKP6 2/20 0.43
AOC1 P19801 1/20 0.43
AOC3 Q16853 1/20 0.43
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
ALDH1A1 P00352 1/20 0.42
LMNA P02545 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
PTGER4 P35408 2/20 0.41
KDM4C Q9H3R0 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29922576 0.98 KDM4E (0.56) MAPTKDM4EGAAAPPHDAC3
SCHEMBL8564453 0.98 KDM4E (0.56) MAPTKDM4EGAAAPPHDAC3
SCHEMBL977627 0.92 PTGER4 (0.47) MAPTKDM4EGAAAPPHDAC3
SCHEMBL30693377 0.92 PTGER4 (0.47) MAPTKDM4EGAAAPPHDAC3
SCHEMBL23997400 0.84 PTGER4 (0.42) MAPTKDM4EGAAAPPHDAC3
SCHEMBL3876083 0.82 NSD2 (0.48) MAPTHDAC3HDAC1HDAC2ACHE
SCHEMBL3872897 0.81 CHRM2 (0.43) MAPTKDM4EGAAHDAC3HDAC1
Hydrochloric Acid SCHEMBL3882481 0.80 CHRM2 (0.42) MAPTKDM4EGAAHDAC3HDAC1
SCHEMBL25274765 0.79 PTGER4 (0.49) MAPTKDM4EHDAC3HDAC1HDAC2
SCHEMBL25274766 0.79 PTGER4 (0.49) MAPTKDM4EHDAC3HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 US disclosed
WO-2019055750-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF Aduro Biotech, Inc. (US) 2019-03-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof NLRP3, NLRP1, P2RX7 MAPT 214/4885KDM4E 1922/4885GAA 1517/4885
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF NLRP3, NLRP1, P2RX7 MAPT 214/4885KDM4E 1922/4885GAA 1517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.